Study on the Safety and Effectiveness of Fecal Microbiota Transplantation for Various Diseases Linked to Intestinal Microbiome Imbalance

What this Trial Is About

Researchers are studying the use of fecal microbiota transplantation FMT to treat a variety of diseases linked to imbalances in the gut microbiome, known as dysbiosis. These diseases include functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral, and neurological conditions. While FMT is already recommended for Clostridium difficile infection, its safety and effectiveness for other dysbiosis-related diseases are still being explored through this pilot study. Participants will receive FMT, which involves transferring feces from a healthy donor into the patients gastrointestinal tract to alter their intestinal microbiota. The study includes various disease groups such as irritable bowel syndrome, ulcerative colitis, Crohns disease, Parkinsons disease, metabolic syndrome, and many others. The treatment is delivered using methods like endoscopy, colonoscopy, capsules, or nasoduodenal tube insertion. During the study, participants gastrointestinal symptoms will be monitored using the Gastrointestinal Symptom Rating Scale over one year to assess FMTs effectiveness. Researchers will also track any treatment-related adverse events using standard criteria. Participants must tolerate the infusion methods, and the study runs until the end of 2026, involving regular assessments and safety monitoring throughout.

Efficacy and Safety of Fecal Microbiota Transplantation